Publications by authors named "Evan Grovenstein"
Article Synopsis
- KP1019, a ruthenium-based anticancer complex, damages DNA and induces apoptosis like platinum-based chemotherapeutics but shows no dose-limiting toxicity in clinical trials.
- A proteomic study in yeast revealed that KP1019 likely causes oxidative stress by increasing antioxidant glutathione levels and altering protein expression involved in ribosome biogenesis and translation.
- Findings suggest that in addition to DNA damage, KP1019 also targets protein metabolism, indicating potential for combination therapies with other drugs like oxaliplatin.
